# Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

* Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease.
* The therapy improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons.
* Findings were presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City.
* CNM-Au8 previously showed positive energetic and metabolic effects in a Phase 2 Parkinson’s trial, aligning with the new preclinical results.
* The treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in ALS and MS trials.
* Clene plans to design a Phase 2 clinical study for Parkinson’s disease while advancing ALS and MS programs.

 Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has presented encouraging preclinical findings for its lead investigational therapy, CNM-Au8, in Parkinson’s disease. The data, announced earlier in September 2025, highlight the drug’s potential to address key cellular and energetic deficits that drive disease progression (https://ibn.fm/EECHU).

 The results were unveiled at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City. Researchers reported that CNM-Au8 improved mitochondrial health, reduced harmful inflammation, restored energy metabolism, and normalized disrupted gene expression in…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/clene-inc-s-nasdaq-clnn-lead-candidate-cnm-au8r-shows-promise-in-improving-cellular-health-in-parkinsons-disease/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/clene-s-cnm-au8-shows-promise-in-parkinson-s-disease-treatment/095d52e140cf6b6ea4797d5ed0d9cc41) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1nir2oz/clenes_cnmau8_shows_promise_in_parkinsons_disease/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/16/nukeamTG.webp)